{
  "docId": "019de075-c3df-7648-ab3f-403a3e018886",
  "docSlug": "132267474e075f06292187997a008f90",
  "documentTitle": "OmniAb | Investor Presentation Deck | 35 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 35,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The chart shows a steady increase in clinical programs from 2016 to mid-2023.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c3df-7648-ab3f-403a3e018886/9",
  "deckHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886",
  "deckJsonHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886.json",
  "deckAnchorHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.23,
        "x": 0.715,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Number of Active Clinical Programs and Approved Products",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6446d891-c1d1-4bb6-9f14-0242b15c5a52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.65,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "2 new programs entered the clinic in Q2\n- IMVT-1402 (Immunovant): Next-generation FcRn antagonist\n- GLS-012 (Gloria): anti-LAG-3\n3 new programs have entered the clinic so far in the first half of 2023\nBased on dialog with our partners, we see potential for 1-2 additional new entries into clinical development for novel OmniAb-derived antibodies in the second half of 2023\nPartner progression also showing the flexibility of our platform, with an increasing number of formats and modalities in clinical or preclinical development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3048998d-5bd4-439c-b38a-c7dbfdc0aaa9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "ACTIVE CLINICAL PROGRAMS AND APPROVED PRODUCTS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9febbf5e-f4c0-4142-bda8-b53778a77579",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Performance Indicators",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "346052a7-d9c6-4fef-87c5-05fb0bd65ca2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "1cc5e654-8eab-4a9a-aafb-1c0cc63ec207",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document presents OmniAb's substantial progress in all phases and growth in discovery programs.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1674fffb-efec-427e-b437-66fc0c0fd01e",
      "evidence": "The document presents the potential consequences of not investing in effective discovery technology.",
      "position": 0,
      "objective": "Highlight the importance of investing in OmniAb's technology to drive growth and success in the biotech industry.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}